IntelliPharmaCeutics International (IntelliPharmaCeutics International) Debt-to-Equity : -0.17 (As of Aug. 2023)

View and export this data going back to 1996. Start your Free Trial

What is IntelliPharmaCeutics International Debt-to-Equity?

IntelliPharmaCeutics International's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Aug. 2023 was $2.22 Mil. IntelliPharmaCeutics International's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Aug. 2023 was $0.00 Mil. IntelliPharmaCeutics International's Total Stockholders Equity for the quarter that ended in Aug. 2023 was $-12.88 Mil. IntelliPharmaCeutics International's debt to equity for the quarter that ended in Aug. 2023 was -0.17.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for IntelliPharmaCeutics International's Debt-to-Equity or its related term are showing as below:

IPCIF' s Debt-to-Equity Range Over the Past 10 Years
Min: -11.28 Med: -0.23 Max: 3.34
Current: -0.17

During the past 13 years, the highest Debt-to-Equity Ratio of IntelliPharmaCeutics International was 3.34. The lowest was -11.28. And the median was -0.23.

IPCIF's Debt-to-Equity is not ranked
in the Biotechnology industry.
Industry Median: 0.15 vs IPCIF: -0.17

IntelliPharmaCeutics International Debt-to-Equity Historical Data

The historical data trend for IntelliPharmaCeutics International's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IntelliPharmaCeutics International Debt-to-Equity Chart

IntelliPharmaCeutics International Annual Data

Trend

Nov13

Nov14

Nov15

Nov16

Nov17

Nov18

Nov19

Nov20

Nov21

Nov22

Debt-to-Equity

Get a 7-Day Free Trial

0.44

-0.52

-0.34

-0.24

-0.22

IntelliPharmaCeutics International Quarterly Data
	Nov18	Feb19	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23
Debt-to-Equity	Get a 7-Day Free Trial															-0.20	-0.22	-0.21	-0.20	-0.17

Competitive Comparison of IntelliPharmaCeutics International's Debt-to-Equity

For the Biotechnology subindustry, IntelliPharmaCeutics International's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

IntelliPharmaCeutics International's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, IntelliPharmaCeutics International's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where IntelliPharmaCeutics International's Debt-to-Equity falls into.

IntelliPharmaCeutics International Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

IntelliPharmaCeutics International's Debt to Equity Ratio for the fiscal year that ended in Nov. 2022 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(2.326	+	0)	/	-10.577
	=	-0.22

IntelliPharmaCeutics International's Debt to Equity Ratio for the quarter that ended in Aug. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(2.218	+	0)	/	-12.876
	=	-0.17

IntelliPharmaCeutics International (OTCPK:IPCIF) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

IntelliPharmaCeutics International Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of IntelliPharmaCeutics International's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

IntelliPharmaCeutics International (IntelliPharmaCeutics International) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IntelliPharmaCeutics International Inc (OTCPK:IPCIF) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

I4AA:Germany IPCI:Canada

Address

30 Worcester Road, Toronto, ON, CAN, M9W 5X2

Website

https://www.intellipharmaceutics.com

IntelliPharmaCeutics International Inc is a pharmaceutical company. The company is engaged in the research, development, and manufacturing of novel and generic controlled-release and targeted-release oral solid dosage drugs. Its patented Hypermatrix technology is a multidimensional controlled-release drug delivery platform that can be applied to the development of a range of existing and new pharmaceuticals. Its ongoing drug development programs are at various stages of development in therapeutic areas that include neurology, cardiovascular, GIT, and pain. The company's product, a generic of Focalin XR, is partnered with Par Pharmaceutical, Inc. and received FDA approval. It derives revenue from the United States.